News

Fulcrum Therapeutics said it is discontinuing development of pociredir, its experimental oral treatment for sickle cell disease (SCD), after the U.S. Food and Drug…

 CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for severe…

With increasing population numbers worldwide, sickle cell disease (SCD) continues to pose a serious global health problem, especially in sub-Saharan Africa, where…

AbstractSickle cell disease (SCD) is an inherited hemoglobinopathy characterized by chronic hemolytic anemia, painful vaso-occlusive episodes, and end organ damage…

ABSTRACTOrbital involvement in sickle cell disease (SCD) is rare but potentially vision-threatening and often misdiagnosed due to overlap with infectious orbital…

A ten-year study has identified significant clinical outcomes for patients with sickle cell anemia treated with hydroxyurea, including reduced mortality rates,…

These are the benefits documented from 10 years of continuous hydroxyurea treatment provided in the NOHARM trial to a group of young children in Uganda, which has…

Sickle cell disease (SCD) is a group of inherited blood disorders that cause red blood cells to become hard, sticky, and crescent-shaped.Instead of flowing smoothly…

AbstractThe US Food and Drug Administration recently approved sickle cell disease (SCD) gene therapies that require a contemporaneous cohort to compare their…

Key Points Non-myeloablative haploidentical (NMAC-HID) transplant would be cost-effective for long-term SCD remission in adultsMaximum gene therapy price…